NOTICE OF UPGRADE
Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022
SEARCH LISTED COMPANY
Any AUS or NZ company
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
25 April 2025
| Name: | ANTISENSE THERAPEUTICS LIMITED (ANP) (This company subsequently changed its name to PERCHERON THERAPEUTICS LIMITED. You should refer to that name for Status.) | ||||||
| ISIN: | AU000000ANP4 | ||||||
| Date of Listing: | 20 December 2001 | ||||||
| Subsequent Names: |
|
Stock Exchange Status: (updated daily)
This company subsequently changed its name to PERCHERON THERAPEUTICS LIMITED. You should refer to that name for Stock Exchange Status.Legal Status: (updated monthly)
ACN: 095 060 745ABN: 41 095 060 745
Registration Date: 13 November 2000
Capital Gains Tax (CGT) Status: (updated at least quarterly)
This company subsequently changed its name and is now PERCHERON THERAPEUTICS LIMITED. You should refer to that name for Capital Gains Tax Status.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
| FROM | TO | |
| PERCHERON THERAPEUTICS LIMITED | 04/01/2024 | |
| ANTISENSE THERAPEUTICS LIMITED | 04/01/2024 |
Boardroom Pty Ltd
Level 8, 210 George Street, Sydney NSW 2000
Tel : +61 2 9290 9600 or 1300 737 760
Fax : +61 2 9279 0664 or 1300 653 459
RegistryWebsite RegistryEmail
Expand this box to read and print
name changed to Percheron Therapeutics Limited | 04/01/2024 |
The suspension of trading in the securities of Antisense Therapeutics Limited will be lifted immediately following the release by ANP of an announcement relating to the request for a trading halt on 15 August 2022. | 19/08/2022 |
The company releases a response to ASX Query. | 19/08/2022 |
The company releases a Long Covid-19 Collaboration Outcomes Presentation. | 19/08/2022 |
World first study utilizing Somalogic SomaScan assay# to assess up to 7,000 plasma proteins in Long COVID-19 patients has elucidated novel blood markers as potential diagnostic and therapeutic targets. Provisional patent applications have been filed in the United States (US) to seek protection for these new inventions. A potential therapeutic marker known to be modulated by ATL1102 in DMD patients has been identified as suggestive of its therapeutic potential as a treatment for Long COVID-19. Collaboration with global leader in the clinical research of neurological aspects of Long COVID-19 Dr Koralnik to continue with application for grant funding. Company plans to review its new patent applications with targeted pharmaceutical and diagnostic companies for potential commercial discussions. | 19/08/2022 |
The securities of Antisense Therapeutics Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of ANP, pending the release of an announcement relating to the request for a trading halt on 15 August 2022. | 17/08/2022 |
The suspension of trading in the securities of Antisense Therapeutics Limited will be lifted immediately, following the release by ANP of an announcement regarding clinical trial results. | 17/12/2019 |
The data from all nine participants having completed their 24 weeks of dosing in the Phase II clinical trial of ANP's immunomodulatory therapy, ATL1102 for Duchenne Muscular Dystrophy has affirmed the drug's excellent safety profile and positive drug effects on disease progression endpoints at the low dose tested and in turn the company's plans to advance ATL1102 into a potentially pivotal Phase IIb clinical trial. | 17/12/2019 |
Antisense enters into an agreement with Morgans Corporate Limited to underwrite the balance of the options not yet exercised or committed, to raise $4.1 million. Total funds raised via the options exercise will be $5.5 million. Funds raised from the issue of the Options intended for use towards advancing plans for Phase IIb clinical trial of ATL1102 in DMD and for general working capital and corporate purposes. | 17/12/2019 |
The securities of Antisense Therapeutics Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of ANP, pending the release of an announcement regarding clinical trial results. | 16/12/2019 |
we understand that on or about this date the company consolidated its shares 1 for 10 | 13/11/2013 |
The suspension of trading in the securities of Antisense Therapeutics Limited (the "Company") will be lifted immediately, following the release of an announcement by the company regarding a capital raising | 23/03/2012 |
The securities of Antisense Therapeutics Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement regarding a capital raising | 23/03/2012 |
name changed to Percheron Therapeutics Limited | 04/01/2024 |
The suspension of trading in the securities of Antisense Therapeutics Limited will be lifted immediately following the release by ANP of an announcement relating to the request for a trading halt on 15 August 2022. | 19/08/2022 |
The company releases a response to ASX Query. | 19/08/2022 |
The company releases a Long Covid-19 Collaboration Outcomes Presentation. | 19/08/2022 |
World first study utilizing Somalogic SomaScan assay# to assess up to 7,000 plasma proteins in Long COVID-19 patients has elucidated novel blood markers as potential diagnostic and therapeutic targets. Provisional patent applications have been filed in the United States (US) to seek protection for these new inventions. A potential therapeutic marker known to be modulated by ATL1102 in DMD patients has been identified as suggestive of its therapeutic potential as a treatment for Long COVID-19. Collaboration with global leader in the clinical research of neurological aspects of Long COVID-19 Dr Koralnik to continue with application for grant funding. Company plans to review its new patent applications with targeted pharmaceutical and diagnostic companies for potential commercial discussions. | 19/08/2022 |
The securities of Antisense Therapeutics Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of ANP, pending the release of an announcement relating to the request for a trading halt on 15 August 2022. | 17/08/2022 |
The suspension of trading in the securities of Antisense Therapeutics Limited will be lifted immediately, following the release by ANP of an announcement regarding clinical trial results. | 17/12/2019 |
The data from all nine participants having completed their 24 weeks of dosing in the Phase II clinical trial of ANP's immunomodulatory therapy, ATL1102 for Duchenne Muscular Dystrophy has affirmed the drug's excellent safety profile and positive drug effects on disease progression endpoints at the low dose tested and in turn the company's plans to advance ATL1102 into a potentially pivotal Phase IIb clinical trial. | 17/12/2019 |
Antisense enters into an agreement with Morgans Corporate Limited to underwrite the balance of the options not yet exercised or committed, to raise $4.1 million. Total funds raised via the options exercise will be $5.5 million. Funds raised from the issue of the Options intended for use towards advancing plans for Phase IIb clinical trial of ATL1102 in DMD and for general working capital and corporate purposes. | 17/12/2019 |
The securities of Antisense Therapeutics Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of ANP, pending the release of an announcement regarding clinical trial results. | 16/12/2019 |
we understand that on or about this date the company consolidated its shares 1 for 10 | 13/11/2013 |
The suspension of trading in the securities of Antisense Therapeutics Limited (the "Company") will be lifted immediately, following the release of an announcement by the company regarding a capital raising | 23/03/2012 |
The securities of Antisense Therapeutics Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement regarding a capital raising | 23/03/2012 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 17/11/2023 | James Garner | 100,000 | $0.061 | $6,100 |
| 26/09/2023 | Gil Price | 400,000 | $0.071 | $28,400 |
| 08/05/2023 | James Garner | 300,000 | $0.074 | $22,200 |
| 03/10/2022 | Gil Price | 701 | $0.084 | $59 |
| 30/09/2022 | Gil Price | 105,208 | $0.086 | $9,048 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Charmaine Gittleson | Non Exec Chairman | 22/03/2021 |
| James Garner | Managing Director, CEO | 08/05/2023 |
| Phillip Hains | CFO, Company Secretary | 09/11/2006 |
| Gil Price | Non Exec Director | 04/10/2021 |
| Alicia Mellors | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Mark Diamond | CEO | 31/10/2001 | 12/05/2023 |
| Gary Pace | Non Exec Director | 09/11/2015 | 17/11/2022 |
| Graham Mitchell | Non Exec Director | 24/10/2001 | 17/12/2021 |
| Robert Moses | Chairman | 23/10/2001 | 15/12/2021 |
| William Goolsbee | Non Exec Director | 15/10/2015 | 15/12/2021 |
| Chris Belyea | Non Exec Director | 13/11/2000 | 12/11/2015 |
| Simon Watkin | Investor Relations | 31/12/2012 | |
| George Werther | Non Exec Director | 23/10/2001 | 02/11/2012 |
| Frank Bennett | Non Exec Director | 31/07/2006 | 15/03/2008 |
| Stanley Crooke | Non Exec Director | 31/10/2001 | 31/07/2006 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2025 Investogain Pty Limited. All rights reserved.
